Active Biotech Interim Report Q2 2022

SECOND QUARTER IN BRIEF

  • Laquinimod eye drop phase I single ascending-dose part in healthy subjects was completed without reported safety concerns, multiple-dose part started
  • Active Biotech strengthened the patent protection for laquinimod in eye disorders (April 26)
  • FDA granted Orphan Drug Designation for tasquinimod in myelofibrosis (May 18)
  • Successful completion of the first stage of the phase IIa clinical study of naptumomab in combination with docetaxel, with the study now enrolling into the second stage (June 1)

EVENTS AFTER THE END OF THE PERIOD

  • The first part of the multiple-dose of laquinimod eye drops in the phase I study has been completed without any serious side effects that can be linked to laquinimod and the study has been expanded with another dose group
  • The board of directors resolved on August 4, 2022, based on the authorisation from the general meeting, to carry out a rights issue of approximately SEK 55 million to secure financing of the ongoing and planned development programs

Financial summary

SEK M Apr-Jun Jan-Jun Full-year
2022 2021 2022 2021 2021
Net sales
Operating profit/loss -14,0 -12,6 -29,3 -22,4 -49,8
Profit/loss after tax -14,3 -12,6 -30,0 -22,4 -49,8
Earnings per share (SEK) -0,07 -0,06 -0,14 -0,11 -0,24
Cash and cash equivalents (at close of period) 21,9 78,5 53,1

The report is also available at www.activebiotech.com.